<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02381678</url>
  </required_header>
  <id_info>
    <org_study_id>Edwards-CN-001</org_study_id>
    <nct_id>NCT02381678</nct_id>
  </id_info>
  <brief_title>A Retrospective Study to Collect the Data From the Patients Who Had the Perimount Heart Valve Replacement Surgery in China During 2001 to 2007</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards (Shanghai) Lifesciences Medical Supplies Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards (Shanghai) Lifesciences Medical Supplies Co.,Ltd.</source>
  <brief_summary>
    <textblock>
      The objective of the study is to obtain the clinical data from patients who had the Perimount
      Heat Valve (Type:6900P and 2900) Replacement Surgery in Guangdong General Hospital during
      2001-2007 in order to evaluate the performace of this heart valve prothesis and collect the
      patients' post-operation infomation including the current living status, mortality rate, and
      the possibility of re-operation，bleeding and thrombosis.

      This is a retrospective , observentional clinical study to be conducted in Guangdong General
      Hospital in China. This study will enroll up to 200 patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The Performance Evaluation of Perimount Heart Valve(Type:6900P and 2900) by Echocardiography</measure>
    <time_frame>7-15 years after heart valve replacement surgery (during 2001-2007)</time_frame>
    <description>This is a one-arm study. All enrolled 225 subjects are required to be back Gungdong General Hospital to do an Echocardiography</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">225</enrollment>
  <condition>Mitral Valve or Aortic Valve Replacement</condition>
  <arm_group>
    <arm_group_label>Subjects implanted with Perimount Heart Valve</arm_group_label>
    <description>Only one group was set for this study, including all enrolled subjects who implanted with Perimount Heart Valve during 2001 to 2007</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Perimount 2900/6900 Heart Valve</intervention_name>
    <description>This is a retrospective study which ask the subjects implanted with Perimount Heart Valve during 2001 to 2007 back hospital for follow up visit.</description>
    <arm_group_label>Subjects implanted with Perimount Heart Valve</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The patients who had the Perimount Heart Valve (Type: 6900P and 2900) Replacement Surgery
        during 2001-2007 in Guangdong General Hospital in China
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patients who implanted with Perimount Heart Valve (Type: 6900P and 2900) during
             2001-2007 in Guangdong General Hospital in China

          -  The patients agree to join the study and sign the ICF

        Exclusion Criteria:

          -  No specific exclusion criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huiming Guo, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2015</study_first_submitted>
  <study_first_submitted_qc>March 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2015</study_first_posted>
  <results_first_submitted>May 26, 2016</results_first_submitted>
  <results_first_submitted_qc>August 22, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 17, 2016</results_first_posted>
  <last_update_submitted>August 22, 2016</last_update_submitted>
  <last_update_submitted_qc>August 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Valve Replacement</keyword>
  <keyword>Perimount 2900</keyword>
  <keyword>China</keyword>
  <keyword>Perimount 6900P</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Investigators find total 253 patients who implanted Perimount Heart Valve during 2001 to 2007 in the Guangdong General Hospital. After the contact with these patients or their relatives, 225 patients agree to join the study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Age Group Under 60 Years Old</title>
          <description>54 subjects implanted Perimount Heart Valve when the age was under 60.</description>
        </group>
        <group group_id="P2">
          <title>Age Group Between 60 and 70 Years Old</title>
          <description>139 subjects implanted Perimount Heart Valve when the age was between 60 and 70 years old (&gt;=60,&lt;70)</description>
        </group>
        <group group_id="P3">
          <title>Age Group Above 70 Years Old</title>
          <description>32 subjects implanted Perimount Heart Valve when the age was above 70</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="139"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="139"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This is one-arm study, all 225 subjects included in the Full Analysis Set.</population>
      <group_list>
        <group group_id="B1">
          <title>All Patients Enrolled in Study</title>
          <description>The whole group included 225 enrolled subjects. All 225 subjects included in the FAS(Full Analysis Set).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="225"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" lower_limit="16" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Etiology of subjects</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Rheumatic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Degenerated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endocardititis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ischemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Miscellaneous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Preoperative Classification of NYHA assessment</title>
          <description>The criteria for NYHA assessment listed below:
Class I: Cardiac disease, but no symptoms and no limitation in ordinary physical activity, e.g. no shortness of breath when walking, climbing stairs etc.
Class II: Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity.
Class III: Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20–100 m).
Comfortable only at rest. Class IV: Severe limitations. Experiences symptoms even while at rest. Mostly bed-bound patients.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Class I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Known</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>The numbers of valves implanted simultaneously</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Single Valve Replacement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Double Valves Replacement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triple Valves Replacement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>The concomitant surgery</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Coronary Artery Bypass Grafting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Atrial Reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tricuspid valvuloplasty</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Radiofrequency Ablation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>The time for Extracorporeal Circulation and Cross Clamp in surgery</title>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Time for Extracorporeal Circulation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="137.9" spread="66.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time for cross clamp</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89.5" spread="40.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Performance Evaluation of Perimount Heart Valve(Type:6900P and 2900) by Echocardiography</title>
        <description>This is a one-arm study. All enrolled 225 subjects are required to be back Gungdong General Hospital to do an Echocardiography</description>
        <time_frame>7-15 years after heart valve replacement surgery (during 2001-2007)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>One-arm Group Included All Enrolled Subjects</title>
            <description>This group included total 225 enrolled participants</description>
          </group>
        </group_list>
        <measure>
          <title>The Performance Evaluation of Perimount Heart Valve(Type:6900P and 2900) by Echocardiography</title>
          <description>This is a one-arm study. All enrolled 225 subjects are required to be back Gungdong General Hospital to do an Echocardiography</description>
          <units>Percentage of all subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Freedom from SVD at 5 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Freedom from SVD at 10 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Freedom from SVD at 15 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall survival rate at 5 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall survival rate at 10 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall survival rate at 15 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All patients implanted with Perimount Heart Valves during 2001 to 2007. And investigators collect these patients' current healthy information and report the safety and efficacy results of a 9-15 year follow-up investigation</time_frame>
      <desc>The serious adverse events for these subjects included death and reoperation. And the adverse events mainly included SVD (structure of valve deterioration)</desc>
      <group_list>
        <group group_id="E1">
          <title>Age Group Under 60 Years Old</title>
          <description>54 subjects implanted Perimount Heart Valve when the age was under 60.</description>
        </group>
        <group group_id="E2">
          <title>Age Group Between 60 and 70 Years Old</title>
          <description>139 subjects implanted Perimount Heart Valve when the age was between 60 and 70 years old (&gt;=60,&lt;70)</description>
        </group>
        <group group_id="E3">
          <title>Age Group Above 70 Years Old</title>
          <description>32 subjects implanted Perimount Heart Valve when the age was above 70</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Death</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="54"/>
                <counts group_id="E2" events="56" subjects_affected="56" subjects_at_risk="139"/>
                <counts group_id="E3" events="22" subjects_affected="22" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Re-operation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>SVD</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>SVD</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="54"/>
                <counts group_id="E2" events="27" subjects_affected="27" subjects_at_risk="139"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Huiming Guo (Chief in Cardiac Surgical Department)</name_or_title>
      <organization>Guangdong General Hospital</organization>
      <phone>86-13609089789</phone>
      <email>guohuiming@vip.tom.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

